Table 2.

Baseline characteristic in the bortezomib study (APEX) and the thalidomide studies

		Thalidomide
Baseline patient characteristic	Bortezomib	Median	Range	No. of studies
Median age, years	62	63	56–69	15
Gender, %male	56	56	44–73	14
IgG:IgA	60:23	70:16	–	7
β2 microglobulin (mg/L)	3.7	3.5	2.9–4.6	6
Disease duration, months	42	44	31–55	9